Oric Pharma Unveils Rinzimetostat Phase Ib Data And Outlines Phase III Study In Prostate Cancer

Oric Pharmaceuticals reported dose-optimization results from its Phase Ib study of Rinzimetostat (ORIC-944) and announced plans to initiate its first Phase III registrational study in metastatic castration-resistant disease. The update advances the program toward registration-directed development and is likely viewed positively by investors, though the release provided no efficacy magnitudes or timing details. Expect stock movement in the single-digit percent range on investor reaction to subsequent data or a formal Phase III start announcement.

Analysis

Oric Pharmaceuticals reported dose-optimization results from its Phase Ib study of Rinzimetostat (ORIC-944) and announced plans to initiate its first Phase III registrational study in metastatic castration-resistant disease. The update advances the program toward registration-directed development and is likely viewed positively by investors, though the release provided no efficacy magnitudes or timing details. Expect stock movement in the single-digit percent range on investor reaction to subsequent data or a formal Phase III start announcement.